JPWO2021041237A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021041237A5
JPWO2021041237A5 JP2022512349A JP2022512349A JPWO2021041237A5 JP WO2021041237 A5 JPWO2021041237 A5 JP WO2021041237A5 JP 2022512349 A JP2022512349 A JP 2022512349A JP 2022512349 A JP2022512349 A JP 2022512349A JP WO2021041237 A5 JPWO2021041237 A5 JP WO2021041237A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
tautomer
acceptable salt
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022512349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544714A (ja
JP7646632B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047467 external-priority patent/WO2021041237A1/en
Publication of JP2022544714A publication Critical patent/JP2022544714A/ja
Publication of JPWO2021041237A5 publication Critical patent/JPWO2021041237A5/ja
Priority to JP2025034294A priority Critical patent/JP2025106242A/ja
Application granted granted Critical
Publication of JP7646632B2 publication Critical patent/JP7646632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022512349A 2019-08-23 2020-08-21 甲状腺ホルモン受容体ベータアゴニスト化合物 Active JP7646632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034294A JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962891078P 2019-08-23 2019-08-23
US62/891,078 2019-08-23
US202062967943P 2020-01-30 2020-01-30
US62/967,943 2020-01-30
PCT/US2020/047467 WO2021041237A1 (en) 2019-08-23 2020-08-21 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034294A Division JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (3)

Publication Number Publication Date
JP2022544714A JP2022544714A (ja) 2022-10-20
JPWO2021041237A5 true JPWO2021041237A5 (enExample) 2023-08-28
JP7646632B2 JP7646632B2 (ja) 2025-03-17

Family

ID=74684314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022512349A Active JP7646632B2 (ja) 2019-08-23 2020-08-21 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2025034294A Pending JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034294A Pending JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (7)

Country Link
US (1) US20220281849A1 (enExample)
EP (1) EP4017875A4 (enExample)
JP (2) JP7646632B2 (enExample)
CN (1) CN114430743A (enExample)
AU (1) AU2020336272A1 (enExample)
CA (1) CA3154488A1 (enExample)
WO (1) WO2021041237A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
FI3965884T3 (fi) 2019-05-08 2025-04-02 Aligos Therapeutics Inc Thr-beetan modulaattoreita, joissa on diokso-1,2,4-triatsyylipääryhmä
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2022011120A1 (en) * 2020-07-10 2022-01-13 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2022037617A1 (zh) * 2020-08-19 2022-02-24 成都凡诺西生物医药科技有限公司 腈代三嗪类衍生物及其制备方法和应用
EP4301357A4 (en) * 2021-03-03 2025-01-22 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN117624073A (zh) * 2021-03-19 2024-03-01 南京明德新药研发有限公司 双环苯酚类化合物及其应用
WO2022242743A1 (zh) * 2021-05-21 2022-11-24 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
CN113979963B (zh) * 2021-12-24 2022-03-11 凯思凯旭(上海)医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787652B1 (en) * 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
PT1088819E (pt) * 1999-09-30 2005-09-30 Pfizer Prod Inc Derivados de 6-azauracilo como lignados de receptores da tiroide
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
HRP20100633T1 (hr) * 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
GB0608724D0 (en) * 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CA2758894C (en) * 2009-04-20 2013-09-10 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone .beta. receptor agonist
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
EP3725779A4 (en) * 2018-01-23 2021-02-24 Shenzhen TargetRx, Inc. SUBSTITUTED PYRIDAZINONE COMPOUND
EP3864013A4 (en) * 2018-10-12 2022-09-28 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN119431265A (zh) * 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
FI3965884T3 (fi) * 2019-05-08 2025-04-02 Aligos Therapeutics Inc Thr-beetan modulaattoreita, joissa on diokso-1,2,4-triatsyylipääryhmä

Similar Documents

Publication Publication Date Title
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
JP2024050527A5 (enExample)
JPWO2020061101A5 (enExample)
JP2019529484A5 (enExample)
JPWO2021041237A5 (enExample)
JP2016506960A5 (enExample)
JP2019512505A5 (enExample)
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
JP2019094345A5 (enExample)
JP2011509309A5 (enExample)
JP2011520896A5 (enExample)
JP2016506959A5 (enExample)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2011511840A5 (enExample)
JP2016514718A5 (enExample)
JP2016509583A5 (enExample)
JP2020507589A5 (enExample)
JP2019501879A5 (enExample)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2019507114A5 (enExample)
JP2017529389A5 (enExample)
JP2014514290A5 (enExample)
JP2013527847A5 (enExample)